BRITISH SOCIETY FOR HAEMATOLOGY

BSH 2021 VIRTUAL

 

25-28 April 2021 Virtual Conference
Close
N. Poster
Poster title
Applicant name
Status
  PO-001 NGS cannot replace standard Fragment Analysis for the Detection of FLT3-ITD Amanda Gilkes Received Received
  PO-002 Shedding smart light on the effectiveness of chemotherapy; using Raman spectroscopy and machine learning to differentiate the effects of cytarabine toxicity and crosstalk of leukaemic and bone marrow stromal cells. Jen May Received Received
  PO-003 EXPRESSION OF CD47 AND CALR IN MYELOPROLIFERATIVE NEOPLASMS: POTENTIAL NEW THERAPEUTICAL TARGETS Ciro Rinaldi Received Received
  PO-004 HIV status does not impact on the outcome of patients with Burkitt lymphoma: a UK analysis Xiao-Yin Zhang Received Received
  PO-005 Efficacy and Safety of Mogamulizumab by Patient Blood Classification Lay Ean Tan Received Received
  PO-006 Isolated drenching night sweats a critical review of 2 Week Wait primary care referral to Birmingham haematology clinicsBirmingham Heartlands, Good Hope and Solihull Hospitals, University Hospitals Birmingham Clare Gardner Received Received
  PO-007 Clinical characteristics and molecular insights into pathogenesis of peripheral T-cell lymphoma: A SEER population-based study of 11,463 patients and biological analysis Qiaoli Li Received Received
  PO-008 Acalabrutinib-related cardiac toxicities in patients with chronic lymphocytic leukaemia: A meta-analysis of randomised controlled trials Thura Htut Received Received
  PO-009 Mechanisms of acquired resistance in B cell malignancies treated with the ive BTK inhibitor (BTKi), tirabrutinib Ross Jackson Received Received
  PO-010 Impact of COVID-19 on peripheral blood stem cell mobilisation for myeloma patients A single centre experience at University College London Hospitals Marquita Camilleri Received Received
  PO-011 Recovery of Ocular Events with Longer-term Follow-up in the DREAMM-2 Study of Single-agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma Alex Medaglia Received Received
  PO-012 Adrenal Insufficiency Following Prolonged Exogenous Steroid Treatment for Graft Versus Host Disease Ann Tivey Received Received
  PO-013 Impact of SARS-CoV-2 (COVID 19 infection) & MDS in the UK: results of a patient survey to document shielding uptake and patient experience following changes to consultation practice. Pramila Krishnamurthy Received Received
  PO-014 Avapritinib Induces Responses in Patients with Advanced Systemic Mastocytosis, Regardless of Prior Midostaurin Therapy Deepti Radia Received Received
  PO-015 CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN (BET) INHIBITOR, AS MONOTHERAPY IN ADVANCED MYELOFIBROSIS PATIENTS REFRACTORY/INTOLERANT TO JAK INHIBITOR: UPDATE FROM PHASE 2 MANIFEST STUDY Mark Drummond Received Received
  PO-016 Secondary haemophagocytic lymphohistiocytosis in hospitalised COVID-19 patients is infrequent and does not lead to increased mortality Andrew Duncombe Received Received
  PO-017 A Machine Learning Approach to Predicting MPN Patients Graeme Greenfield Received Received
  PO-018 ITP and its management in the UK during the COVID-19 pandemic: interim results of a national audit. Edmund Watson Received Received
  PO-019 Fostamatinib Treatment of Warm Antibody Autoimmune Hemolytic Anemia: A Global, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Duncan Stacey Received Received
  PO-020 Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Morag Griffin Received Received
  PO-021 Assessment of the Longitudinal Effects of Luspatercept on Iron Overload and Iron Chelation Therapy Usage in Adults With -thalassaemia Enrolled in the Phase 3 BELIEVE Study Karolina Lech Received Received
  PO-022 A Retrospective Analysis From Patients Treated in The MEDALIST Study: Safety and Efficacy Of Luspatercept Treatment In Patients With Myelodysplastic Syndrome/Myeloproliferative Neoplasm With Ring Sideroblasts And Thrombocytosis Sheema Sheikh Received Received
  PO-023 Haematological Indices and Haemoglobin High Pressure Liquid Chromatography for diagnosis of Haemoglobinopathies in a Secondary care centre in North East India Mahendra Mishra Received Received
  PO-024 Eligibility for emerging therapies in sickle cell disease Sona Vora Received Received
  PO-025 COVID-19 VTE Champions: a supportive quality improvement programme that optimised thromboprophylaxis in patients with COVID-19 Rebecca Price Received Received
  PO-026 The development of an ambulatory community service for post HSCT patients to promote shielding during the SARS-CoV-2 pandemic Rebecca Hallam Received Received
  PO-027 Use of machine learning-enabled scenario-based teaching in Haematology and Biomedical Science, as a replacement and supplement to traditional tools and in-person teaching during COVID-19. Jen May Received Received
  PO-028 One Step At A Time: Delivering A Safe Laboratory Service For Transfusion Victoria Tuckley Received Received
  PO-029 Joint Health Outcomes in Patients with Hemophilia A Receiving Antihemophilic Factor (Recombinant) in a Real-world Setting: Results of a 6-year Interim Analysis of the AHEAD International Study Kate Khair Received Received
  PO-030 DOES APIXABAN PRETREATMENT ALTER ALTEPLASE-INDUCED THROMBOLYSIS: AN IN VITRO STUDY? Sandra Thalerová Received Received
  PO-031 Point of Care Testing to monitor Vitamin K Antagonist International Normalised Ratio (INR) control in patients with Antiphospholipid Syndrome during the COVID-19 pandemic Michael Masucci Received Received
  PO-032 Quality of life and its predictors among adult patients with haemophilic arthropathy Roberto Ucero-Lozano Received Received
  PO-033 Anthracycline-induced cardiomyopathy in paediatric acute myeloid leukaemia-A single centre age-stratified retrospective analysis and the early impact of dexrazoxane Claire Horgan Received Received
  PO-034 A regional experience of NGS Myeloid panels in Myeloid Haematological malignancies Ferkhanda Zareen Received Received
  PO-035 Response of Immunosuppressive Therapy in patients of Acquired Aplastic Anaemia: Real world experience from a developing country Sobia Umar Received Received
  PO-036 Prognostic significance of BAALC expression in cytogenetically normal acute myeloid leukemia Anita Chopra Received Received
  PO-037 The Molecular Landscape of Acute Myeloid Leukaemia in Northern Ireland Graeme Greenfield Received Received
  PO-038 Cytogenetic and mutational profile analysis of CD56-positive Acute Myeloid Leukaemia: A single centre experience Vita Ceidiene Received Received
  PO-039 Use of Non-funded Drugs in advanced haematological malignancies Asma Batool Received Received
  PO-040 CARBOHYDRATE COMPONENTS OF GLYCOCONJUGATES OF BLAST CELL MEMBRANES IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS Olha Shalay Received Received
  PO-041 An audit of fever-2-needle time in haemato-oncology patients during COVID-19. Sasha-Nicole Temple Received Received
  PO-042 Ensembl variant effect predictor results and other phenotypes reported on the clinically pathogenic variants identified on patients with CD56-positive Acute Myeloid Leukaemia Mahesh Prahladan Received Received
  PO-043 Real-Life Efficacy of Fixed-Dose Hypomethylating Agents in Older Patients with Acute Myeloid Leukemia: A Single Center Experience Tarinee Rungjirajitranon Received Received
  PO-044 Myeloid sarcoma: a single centre experience Christopher Mullen Received Received
  PO-045 Spontaneous regression of acute myeloid leukemia following SARS-CoV-2 infection Kinda Al-Hourani Received Received
  PO-046 All-trans retinoic acid induced myocarditis as a feature of differentiation syndrome: a case report and literature review Na Hyun Kim Received Received
  PO-047 FLT3-ITD negative relapse following FLT3 inhibition Christopher Mullen Received Received
  PO-048 A case of thrombotic stroke in a newly diagnosed APML. Mohammed Hatata Received Received
  PO-049 Diagnostic yield and safety of splenic core biopsy A single Centre experience Francis Anyanwu Received Received
  PO-050 Patient feedback on Lymphoma services during the COVID pandemic charlotte bloodworth Received Received
  PO-051 A Clinical Audit of Discharge Plans for Haemato-oncology Inpatients at Queen Elizabeth Hospital, Birmingham; Implementing the Safe Discharge Guideline. Iman Qureshi Received Received
  PO-052 Impact of the Covid-19 Pandemic on Haematology Research Trials at The Christie Hospital Sana Saleem Received Received
  PO-053 The On-Control Powered Bone Marrow Device: an Audit of 100 Patients in Oxford Faye Sharpley Received Received
  PO-054 Should we replace telephone with video consultation to improve patient experience? - The Queen Elizabeth Hospital experience Matthew Horan Received Received
  PO-055 The Impact of the COVID19 Pandemic on the Diagnosis of Myeloid Malignancies: a Single Institution Experience. Razan Elbashir Received Received
  PO-056 Assisting Trainees with Differential Leucocyte Count Experiment using Deep Learning Techniques Sakthi Jaya Sundar Rajasekar Received Received
  PO-057 Local Safety Standards for Invasive Procedures (LocSSIPs) in Haematology Zeba Ahmed Received Received
  PO-058 Audit of uptake and user satisfaction of Attend Anywhere video consultations in Haematology outpatients QHB Mariyam Eman Iqbal Received Received
  PO-059 Haematology Teams Handover: Improving Communication, Improving Patient Safety. Iman Qureshi Received Received
  PO-060 Educational preferences in Maternal Haematology- A needs assessment Sajida Kazi Received Received
  PO-062 Educational Videos on Haematology Practical Procedures: A UK First in Online High-Quality Open Access Resources Angharad Everden Received Received
  PO-063 Assessment of Anti A and anti B IgM Titre Levels Among Aphaeresis Platelet Donors at National Blood Centre Achana Obris Received Received
  PO-064 A Nurses experience of becoming a Chief Investigator and how they can benefit the wider Haematology research team Emma Williams Received Received
  PO-065 Building Resilience in Face of Change Fatigue Sarah Whitaker Received Received
  PO-067 Liaison haematology: starting to quantify the hidden patient need Gillian Lowe Received Received
  PO-068 CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN (BET) INHIBITOR, IN COMBINATION WITH RUXOLITINIB, IN JAK-INHIBITOR-NAVE MYELOFIBROSIS PATIENTS: UPDATE OF MANIFEST PHASE 2 STUDY Adam Mead Received Received
  PO-069 Advanced systemic mastocytosis with clonal emergence of acute myeloid leukaemia while receiving the KIT D816V inhibitor avapritinib: successfully managed by allogeneic haematopoietic cell transplantation. Priya Sriskandarajah Received Received
  PO-070 CPI-0610, BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN (BET) INHIBITOR, AS ADD-ON TO RUXOLITINIB, IN ADVANCED MYELOFIBROSIS PATIENTS WITH SUBOPTIMAL RESPONSE: UPDATE OF MANIFEST PHASE 2 STUDY Tim Somervaille Received Received
  PO-071 An interesting case highlighting the need to test for JAK2 fusions Christopher Mullen Received Received
  PO-072 A Longitudinal Population-Level Analysis of Healthcare Resource Utilization and Morbidities in Idiopathic Multicentric Castleman Disease Patients Martin Todd Received Received
  PO-073 Long-term Safety of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Treating Immune Thrombocytopenia and Rheumatoid Arthritis Duncan Stacey Received Received
  PO-074 MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF CPI 0610 AND RUXOLITINIB VS. PLACEBO AND RUXOLITINIB IN JAKI-TREATMENT-NAIVE MYELOFIBROSIS PATIENTS Adam Mead Received Received
  PO-075 Abnormal serum protein electrophoretic pattern of patients with severe Sars-CoV-2 infection in the Intensive Care Unit reveals very high levels of dimeric form of alpha-2-macroglobulin Mahesh Prahladan Received Received
  PO-076 HYPOPHOSPHATEMIA FOLLOWING FERRIC CARBOXYMALTOSE (FCM) INFUSIONS AND ITS ASSOCIATED FACTORS Lawanya Wijesekara Received Received
  PO-077 A survey of healthcare professionals in the United Kingdom to describe current pathways and management practices in chronic myeloid leukaemia: the ADAPT CML survey Onyinye Diribe Received Received
  PO-078 Real-World Survival Among Patients With Intermediate- to High-Risk Myelofibrosis in the United States: Impact of Ruxolitinib Approval Srdan Verstovsek Received Received
  PO-079 Outcomes of Haematology Patients Requiring Admission to ICU: Experience from a UK Tertiary Centre Alexander Glover Received Received
  PO-080 ITP treatment-associated osteoporosis risk assessment in a Haematology cohort Mark Ferguson Received Received
  PO-081 Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in the United Kingdom (TRAPeze UK study) Emma Geldman Received Received
  PO-082 Are advisory letters an acceptable alternative to in-person outpatient clinic reviews? A retrospective analysis of referrals to a haematology outpatient clinic Fiona Lynott Received Received
  PO-083 Utility of urinary prostaglandin & N methyl histamine measurements across mast cell disorders (Mastocytosis, Hereditary Alpha Tryptasemia and Mast cell activation syndromes) Bethan Myers Received Received
  PO-085 Management of anaemia in medical oncology patients in a day unit setting. Katrina Fordwor Received Received
  PO-086 The outcome following a COVID-19 diagnosis on haematology patients; data from the South East Scotland Cancer Network Sarah Beverstock Received Received
  PO-087 A review of primary care electronic advice requests to a tertiary centre Haematology department. Eamon Mahdi Received Received
  PO-088 Features of the Course of Various Clinical Forms of Polycythemia Vera. Fidan Khalilova Received Received
  PO-089 Preliminary gastrointestinal safety and tolerability of fedratinib from the phase IIIb FREEDOM trial in patients with intermediate- or high-risk myelofibrosis previously treated with ruxolitinib Claire Harrison Received Received
  PO-090 A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104) Catrina Tice Received Received
  PO-091 A Phase 1 Study of INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis (INCB 57643-103) Catrina Tice Received Received
  PO-092 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Parsaclisib Plus Ruxolitinib in Patients with Myelofibrosis Who Have Suboptimal Response to Ruxolitinib Catrina Tice Received Received
  PO-093 Long-term efficacy of first-line versus second-line pegylated interferon in the treatment of essential thrombocythaemia and polycythaemia vera - results of a single-centre retrospective audit Daniel James Received Received
  PO-094 PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physicians Choice in Patients with Primary or Secondary Myelofibrosis and Severe Thrombocytopenia Allison Baker Received Received
  PO-095 Pre-operative anaemia pathway for elective orthopaedic surgery at Manchester University Foundation Trust (MFT) Yasmin Samir Received Received
  PO-096 A Two-Part Phase 2 Study of Itacitinib Immediate Release in Patients with Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy Catrina Tice Received Received
  PO-097 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor TreatmentNave Myelofibrosis Catrina Tice Received Received
  PO-098 Development of a prescribing checklist: implementing change to improve the safety and accuracy of rasburicase prescribing in chemotherapy patients Elizabeth Brook Received Received
  PO-099 Impact of JAK2V617F Mutation on Coagulation Function Tests and Inflammatory Markers in Sudanese Patients with Essential Thrombocythemia Sahar Elbaget Received Received
  PO-100 Experience with Pegasys in patients with Myeloproliferative Neoplasm Jaymathi Dhanapal Received Received
  PO-101 Management of postpartum anaemia Catherine Prodger Received Received
  PO-102 TREATMENT FREE REMISSION IN TUNISIAN PATIENTS WITH CHRONIC MYELOID LEUKEMIA Rim Frikha Received Received
  PO-103 Efficacy and Safety of Pegylated Interferon in Myeloproliferative Neoplasms A Regional Experience. Eileen Ryan Received Received
  PO-104 A case of polycythaemia vera treated with ropeginterferon-2b during pregnancy Irene Sanchez Received Received
  PO-105 A Diagnostic Conundrum: Coombs-negative, Steroid Refractory Hemolytic Anemia with Reduced Reticulocyte Index Despite a Functioning Marrow Scott Mayer Received Received
  PO-106 Dramatic constitutional deterioration following switch to generic imatinib: a case report and one centres experience Kinda Al-Hourani Received Received
  PO-107 Effect of Metformin-induced Serum Vitamin B12 Deficiency on Haematological parameters in Type 2 diabetes patients. Alozie Eze Received Received
  PO-108 Resolution, following treatment with rasburicase, of obstructive nephropathy caused by uric acid calculi as a presenting feature of chronic myeloid leukaemia Tom Bull Received Received
  PO-109 Review of Intrapartum Management of ITP in Pregnancy in John Radcliffe Hospital Jaymathi Dhanapal Received Received
  PO-110 THE TREATMENT OF CHRONIC MYELOID LEUKAEMIA WITH TYROSINE KINASE INHIBITORS - A SINGLE CENTRE RETROSPECTIVE REVIEW Fiona Lynott Received Received
  PO-111 A bone marrow diagnosis: metastatic melanoma with no primary Sarah Beverstock Received Received
  PO-112 The Diagnosis, Treatment and Monitoring of Patients with Chronic Myeloid Leukaemia: The Impact of ELN Guidelines on Clinical Practice in a District General Hospital Muttuswamy Sivakumaran Received Received
  PO-113 Does Obstructive Sleep Apnoea Really Cause Polycythaemia? Sally Keat Received Received
  PO-114 A Rare Case of Posterior Reversible Encephalopathy Syndrome in Acute Intermittent Porphyria leading to seizures and cardiac arrest Arina Madan Received Received
  PO-115 The effect of an ambulatory care pathway on management of anaemia in a district general hospital Pooja Mahapatra Received Received
  PO-116 Evaluation of a new reticulated platelet parameter using an ADVIA 2120i Graham Gibbs Received Received
  PO-117 Knowledge and attitude towards blood donation and prevalence of hepatitis B and C among secondary school teachers in Calabar, Nigeria Patience Akpan Received Received
  PO-118 An audit of blood transfusions on an inpatient haematology unit in an English teaching hospital: what percentage of transfusions are given overnight and what factors contribute to this? Amanda Adams Received Received
  PO-119 Choosing the platform for ABO antibody titration Divya Setya Received Received
  PO-120 Hematological laboratory results and clinical outcome in pregnancy with SARS-COVID-19 infection, a single centre case control study Farooq Wandroo Received Received
  PO-121 Impact of the SARS-Cov-2 (COVID-19) viral pandemic on Blood Transfusion laboratory activity, including pre-transfusion testing and blood component utilisation: A Single-centre Experience Prabal Mittal Received Received
  PO-122 Rationalising Pre-Operative Trauma Bloods Can Lead to Significant Cost Savings David Keohane Received Received
  PO-123 Knowledge, attitudes and practices surrounding voluntary non-remunerated blood donation among medical and non-medical students at The University of the West Indies in Trinidad and Tobago kenneth charles Received Received
  PO-124 Single centre review of granulocyte use Rodothea Amerikanou Received Received
  PO-126 RhD cell-free fetal DNA screening results in reduction of anti-D use at Guys and St Thomas Hospital Charlene Furtado Received Received
  PO-128 An audit of allocation of Paedipacks to polytransfused neonates in a tertiary neonatal unit Frederick Soole Received Received
  PO-129 Can haematological markers of COVID-19 positive patients at presentation to hospital predict subsequent Intensive Treatment Unit (ITU) admission and mortality? Sami Hussain Received Received
  PO-130 Diagnosis and management of a patient with probable alloantibody towards the universal Kell antigen (Ku) Susudu Jayanetti Received Received
  PO-131 Avoidable Out-of-Hours Red Cell Transfusions: A Retrospective Audit at a District General Hospital Joanna Fawcett Received Received
  PO-132 A Low Mean Platelet Volume Indicates Active Inflammatory Bowel Disease; A Sensitive Model in Resource Poor Settings. Hirosha Fernando Received Received
  PO-133 A review of granulocyte use in Scotland for the year 2020. Dáire Quinn Received Received
  PO-134 Investigation of ABO-incompatible RBC transfusions in a tertiary care hospital in Tunis Mahjoub Sonia Received Received
  PO-135 Red cell transfusion practices and the clinical outcome of transfusion among neonates in the Neonatal Intensive Care unit Sri Jayewardanepura General Hospital Sri Lanka. Sachintha Abeyrathna Received Received
  PO-136 Determinants of voluntary blood donation among female students in a tertiary institution in Nigeria Mutiat Ogunfemi Received Received
  PO-137 To improve efficiency of haematology junior doctor working by reducing ad hoc G&S sample requests-A Quality Improvement Project Maira Hafeez Received Received
  PO-138 Abnormal haematological parameters in COVID 19 positive patents. A single centre study from the United Kingdom. Mahesh Prahladan Received Received
  PO-140 A RETROSPECTIVE ANALYSIS OF THE ASSOCIATION OF IRON DEFICIENCY STATUS AND ITS EFFECT ON SEVERITY IN PATIENTS WITH DENGUE FEVER IN A TERTIARY CARE HOSPITAL IN SRI LANKA Dinesh Ranasinghe Received Received
  PO-141 Usage of Therapeutic plasma Exchange(TPE) in leptospirosis associated severe pulmonary haemorrhagic syndrome SANDUN MAHESHA GUNAWARDENE Received Received
  PO-142 Case Report: Therapeutic Plasma Exchange in Acute Liver Injury Following Paracetamol Over Dose Pabasara Premarathne Received Received
  PO-143 G-6-PD Deficiency in Crete, Greece during the last five years. Maria Maisi Received Received
  PO-144 Acalabrutinib (Acala) vs Idelalisib plus Rituximab (IdR) or Bendamustine plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results Abraham Jacob Received Received
  PO-145 Pirtobrutinib (LOXO-305), a next generation highly ive non-covalent Brutons Tyrosine Kinase inhibitor in previously treated mantle cell lymphoma and other non-Hodgkin lymphomas: Results from the phase 1/2 BRUIN study Toby Eyre Received Received
  PO-146 Long-Term Survival and Gradual Recovery of B Cells in Patients With Refractory Large B-Cell Lymphoma Treated With Axicabtagene Ciloleucel Kayla Lane Received Received
  PO-147 Brentuximab vedotin with chemotherapy for previously untreated, stage III/IV classical Hodgkin lymphoma: 5 year update of the ECHELON 1 study John Radford Received Received
  PO-148 Prophylactic Corticosteroid Use With Axicabtagene Ciloleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma Kayla Lane Received Received
  PO-149 Retreatment With Axicabtagene Ciloleucel in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5 Kayla Lane Received Received
  PO-150 Transcriptional Suppression of WEE1 and PARP1 genes improve Sensitivity to Rituximab: A Novel Promising targets to overcome drug Resistance in Diffuse Large B-Cell Lymphoma Nashwa El-Khazragy Received Received
  PO-151 CheckMate 436: Primary efficacy and safety analysis of the phase 2 study evaluating nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma Graham Collins Received Received
  PO-152 The risks of hematological toxicities and bleeding with acalabrutinib in the treatment of chronic lymphocytic leukaemia Thura Htut Received Received
  PO-153 Extrapolating progression free survival curves in chronic lymphocytic leukaemia (CLL) using peripheral blood minimal residual disease (MRD) measurements from venetoclax trials Daniel Martins Received Received
  PO-154 A Phase 1 Study Of CC-92480, A Novel CELMoD Agent, In Patients With Relapsed/Refractory Multiple Myeloma: Pharmacodynamic Effects Of Dose And Schedule Eleni Tsepa Received Received
  PO-155 Population-based cohort study of the efficacy of Brentuximab-Vedotin in relapsed Systemic Anaplastic Large Cell Lymphoma using Public Health England data Sarah Halligan Received Received
  PO-156 Parathyroid hormone levels and prognosis in multiple myeloma? Joanna Tung Received Received
  PO-158 Atypical Infections with BCRi: Real World Data in Chronic Lymphocytic Leukaemia Patients from a London Tertiary Referral Centre Hanna Renshaw Received Received
  PO-159 The psychological impact of the COVID-19 pandemic on Multiple Myeloma patients Michael Campbell Received Received
  PO-160 Patient preferences, treatment satisfaction and quality of life in newly diagnosed and relapsed/refractory multiple myeloma patients receiving injectable-containing or fully oral therapies: the EASEMENT study Neil Rabin Received Received
  PO-161 The Promoting Individualised Self-Management and Survivorship (PrISMS) clinic - a multidisciplinary remote monitoring clinic for a patient-centred approach in multiple myeloma Catherine Lecat Received Received
  PO-162 Thromboprophylaxis in patients with myeloma on imid therapies - an audit of outcomes following introduction of direct oral anticoagulants. Fatima Jamil Received Received
  PO-163 Risk for infections with selinexor in patients with relapsed/refractory multiple myeloma: a systematic review of clinical trials James Wu Received Received
  PO-165 Single Centre Real World Experience of the Management of Elderly Patients with High Grade Non-Hodgkin Lymphoma Using Rituximab, Cyclophosphamide and Etoposide Angharad Everden Received Received
  PO-166 Identifying a subgroup of patients with asymptomatic myeloma who have a low risk of disease progression and long duration of stable disease Philip Cannon Received Received
  PO-167 Service improvement and re-design during the COVID-19 Pandemic: sharing our Myeloma clinic experience Mai Khalifa Received Received
  PO-168 The first Early Access to Medicines Scheme in Relapsed and Refractory Multiple Myeloma Sheetal Fermahan Received Received
  PO-169 Teenage & Young Adult Haematology Patients Have Low Antibody Levels After Standard Chemotherapy Which Respond To Post-Treatment Immunisation Lucinda Eve Sanders Received Received
  PO-170 The impact of isatuximab treatment on monitoring monoclonal protein concentration in myeloma Rachel Wheeler Received Received
  PO-171 Are there any variables and clinical significance in length of stay for patients with diffuse large B-cell lymphoma receiving high dose methotrexate prophylaxis for central nervous system relapse? Maxine Rudkin Received Received
  PO-172 Glioblastoma, IDH-wildtype a new association with IgM paraproteinaemic neuropathy? Dana Lewis Received Received
  PO-173 An Automated Pipeline to Assess Treatment Response and Treatment Eligibility in Myeloma Thomas Coats Received Received
  PO-174 Fracture risk in lymphoma: no longer a bone of contention Keir Pickard Received Received
  PO-175 Has COVID-19 affected the presentation of patients with lymphoid malignancies? Sarah Beverstock Received Received
  PO-176 Real world outcomes of fourth line daratumumab for relapsed/refractory myeloma in two UK centres Sophie Smith Received Received
  PO-177 Real world single-centre experience of daratumumab monotherapy in heavily pretreated relapsed/ refractory multiple myeloma Irene Sanchez Received Received
  PO-178 Incidence of fragility fracture risk factors and management of bone related complications in people treated for Lymphoma with glucocorticoid containing regimens, a single centre experience. charlotte bloodworth Received Received
  PO-179 Improved outcome in elderly patients with advanced stage Diffuse Large B-Cell Lymphoma if completion of intended 6 cycles of R-CHOP21: A single centre study of patients receiving first-line treatment for DLBCL Annabel Hill Received Received
  PO-180 Case series: Transformed Follicular Lymphoma treated with Lenalidomide Nicholas Lafferty Received Received
  PO-181 Bone Marrow Biopsy in the Staging of Hodgkin Lymphoma - Breaking the Habit Michael Caruana Dingli Received Received
  PO-182 An Audit of 2 Week Wait Referrals to the Lymphoma Clinic at University Hospital Southampton Before and During the Coronavirus Pandemic Nicola Campbell Received Received
  PO-183 DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Alex Medaglia Received Received
  PO-184 Central Nervous System Aspergillosis Complicating Ibrutinib Chemotherapy: A Case Series Sally Keat Received Received
  PO-185 Experience in a Large District General Hospital of Excision versus Core Needle Lymph Node Biopsy over a Five Year Period Chibuzo Mowete Received Received
  PO-186 Apixaban in the prevention of thromboembolism in patients with Multiple Myeloma receiving immunomodulatory medications. Real world experience - data from two centers in North Wales, United Kingdom Aswathi Balakrishnan Received Received
  PO-187 Microsatellite aberrations dynamics in relapse and progression of follicular lymphoma Kseniia Sychevskaya Received Received
  PO-188 Infectious complications related to the treatment of Chronic Lymphocytic Leukaemia: Comparison of risks associated with chemoimmunotherapy and ibrutinib Katriona Hutchison Received Received
  PO-189 DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone vs Pomalidomide plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Alex Medaglia Received Received
  PO-190 Impact of comorbidity on therapeutic intent and treatment outcomes in older adult patients with diffuse large B-cell lymphoma Karen Valdés Díaz Received Received
  PO-191 BISPHOSPHONATE USE IN MULTIPLE MYELOMA: AN AUDIT OF COMPLIANCE AND COST ANALYSIS Daniel Farrugia Received Received
  PO-192 The Management of Lymphoma and Chronic Lymphocytic Leukaemia Patients On Long Term Intravenous Immunoglobulin Replacement Therapy: A Single Centre Experience. Nagah Elmusharaf Received Received
  PO-193 A retrospective single-centre cohort study of the efficacy and safety of daratumumab with bortezomib and dexamethasone therapy for previously treated multiple myeloma Irene Sanchez Received Received
  PO-194 Long-term survival outcomes in Multiple Myeloma: A single centre experience Zong Xuan Lee Received Received
  PO-195 The significance of lymphocytosis in routine clinical practice: data from the South East Scotland Cancer Network Gabrielle Clark Received Received
  PO-196 A Different Person Entirely: Adolescent and Young Adults Experiences Returning to Education after Treatment for Haematological Malignancies Cameron Magrath Received Received
  PO-197 How does survival differ by treatment route in elderly DLBCL? Catherine Turner Received Received
  PO-198 Multicentre analysis on the outcome and incidence of invasive cerebral aspergillosis in haemato-oncology patients following ibrutinib treatment Mahesh Prahladan Received Received
  PO-199 Audit and case series of Primary CNS lymphoma at a single centre between 2010 and 2020 excluding those treated with MATRIX chemotherapy or Autologous Stem Cell Transplant. Patrick Sarkies Received Received
  PO-200 Immunoglobulin replacement therapy - The unexpected advantages of a Pandemic in one Haematology Unit Ramya Ramya Received Received
  PO-201 Immunotactoid Glomerulonephritis in a donor kidney Chinonye Onyeocha Received Received
  PO-203 Management of patients with Diffuse Large B cell Lymphoma not fit for anthracycline based chemotherapy at North Wales Cancer Center: Durgadevi Moratuwagama Received Received
  PO-204 A Single Centre Study to Assess Awareness Among Health Care Professionals of Vaccination Advice in Chronic Lymphocytic Leukaemia Grace Cox Received Received
  PO-205 C3 Inhibition with Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Paddock and Palomino Trials Raymond Wong Received Received
  PO-206 The Effect Of Luspatercept On Erythropoiesis Biomarkers In MEDALIST Trial Patients With Lower-Risk Myelodysplastic Syndromes James Matthews Received Received
  PO-207 Superiority of Pegcetacoplan Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria, Regardless of Prior Transfusion Requirement: Analysis at 16-weeks of PEGASUS Phase 3 Randomized Trial Régis Peffault de Latour Received Received
  PO-208 Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Previously Treated with Eculizumab: A Matching-Adjusted Indirect Comparison Rachel Bhak Received Received
  PO-209 Effects of Luspatercept on Health-Related Quality Of Life Outcomes For Patients With Transfusion-Dependent Beta-Thalassaemia In The BELIEVE Trial Jacqueline Moy Received Received
  PO-210 Risk Factors for Thrombotic Events in Patients with PNH: A Nested Case-Control Study in the International PNH Registry Colin Griffim Received Received
  PO-211 High sensitivity PNH Clone testing in Patients with hematological disorders Zohra Farooq Received Received
  PO-212 Improvements in Fatigue and Physical Function Evaluated Through Changes in Clinical Outcomes in Paroxysmal Nocturnal Hemoglobinuria: Post-Hoc Analyses from the PEGASUS Study David Cella Received Received
  PO-213 Discharge opioid prescribing in patients with sickle cell anaemia after an admission for a sickle cell crisis Constantina Pitsillides Received Received
  PO-214 Serum ferritin is under requested in the 1 to 5 age group: Relationship between mean corpuscular volume and serum ferritin Grainne Okeeffe Received Received
  PO-215 Efficacy and safety of ravulizumab in older patients aged 65 years with paroxysmal nocturnal hemoglobinuria in the 301 and 302 phase 3 extension studies Colin Griffin Received Received
  PO-216 The Unique Therapeutic Mechanisms in a Sickle Cell Pain Management Programme Ji Yeon Park Received Received
  PO-217 Effect of Pegcetacoplan on Quality of Life in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Pegasus Phase 3 Trial Comparing Pegcetacoplan to Eculizumab Alexander Rth Received Received
  PO-218 Injection-Site Reactions in the Randomized Phase 3 PEGASUS Trial of Pegcetacoplan Compared with Eculizumab for Individuals with Paroxysmal Nocturnal Hemoglobinuria Vivek Sharma Received Received
  PO-219 Efficacy and Safety of Concomitant Use of Ravulizumab and IST in Patients with Paroxysmal Nocturnal Hemoglobinuria up to 52 Weeks Colin Griffin Received Received
  PO-220 Incomplete Complement Inhibition In Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH) On Eculizumab - 5 Year Experience From The National PNH Service Leeds Rachael Jones Received Received
  PO-221 The use of hydroxycarbamide in sickle cell patients across the South Thames Sickle and Thalassaemia Network Kathryn McVinnie Received Received
  PO-222 Methaemoglobinemia and G6PD in a patient for major surgery: Diagnostic dilemma & therapeutic enigma Arun V J Received Received
  PO-223 Transfusion requirements in adult patients with paroxysmal nocturnal hemoglobinuria with or without a history of bone marrow disorder receiving ravulizumab and eculizumab: results from a phase 3 non-inferiority study extension Colin Griffin Received Received
  PO-224 A delayed diagnosis of Blue rubber bleb nevus syndrome: characterized by refractory iron deficient anemia Qiaoli Li Received Received
  PO-225 EPIDEMIOLOGICAL CHARACTERS OF ADULT EGYPTIAN SICKLE CELL ANEMIA PATIENTS: A SINGLE CENTER EXPERIENCE Mohamed Elbogdady Received Received
  PO-226 EPIDEMIOLOGICAL CHARACTERS OF ADULT EGYPTIAN Auto Immune Heamolytic ANEMIA PATIENTS: A SINGLE CENTER EXPERIENCE Mohamed Elbogdady Received Received
  PO-227 Thalassemia awareness among Iraqi people in 2018 Hashim Talib Hashim Received Received
  PO-228 Implications of the Covid-19 Pandemic for Patients on Long-term Anticoagulants: A DOAC Switching Program in a Teaching Hospital Based Anticoagulant Service Lishel Horn Received Received
  PO-229 Chronic oral anti coagulation and COVID-19; Does it make any difference? Ammar Ashfaq Received Received
  PO-230 Reversal of anticoagulation with PCC every minute counts Jennifer Davies Received Received
  PO-231 Use of the HemosIL Acustar ADAMTS13 functional assay as the basis for Bethesda style inhibitor detection in acquired Thrombotic Thrombocytopaenic Purpura Ana Vaz Received Received
  PO-232 Management of Spontaneous Intra-Cranial Haemorrhage whilst on a Direct Oral Anticoagulant is less well known than Warfarin Elizabeth Ryan Received Received
  PO-233 Major non elective orthopaedic surgery on a severe haemophilia A patient on emicizumab (without inhibitors): a case study Udaya Reddy Received Received
  PO-234 For women with a previous venous thromboembolism, is standard dose thromboprophylaxis adequate in pregnancy? Bethan Myers Received Received
  PO-235 Virtual clinics The Future of Thrombosis and Anticoagulant Consultations? A patient Preference Survey. Nicole Makariou Received Received
  PO-236 Thromboprophylaxis and the D-Dimer in critically unwell patients with Covid-19. A UK single centre experience. Olga Tsiamita Received Received
  PO-237 ADAMTS13 activity trends in TTP patients with COVID-19 infection Rebecca Jane Shaw Received Received
  PO-238 Optimising COVID-19 thromboprophylaxis within the critical care unit of a large UK-based teaching hospital Louis Gardner Received Received
  PO-239 Perioperative management of anticoagulation: an audit of complications Paul Armitage Received Received
  PO-240 Management of surgery, menorrhagia and child-birth for patients with unclassified bleeding disorders: a systematic review of cohort studies Michael Desborough Received Received
  PO-241 Assessing the utility of the pregnancy-adapted YEARS algorithm in predicting presence of PE in pregnant women with suspected PE. Bethan Myers Received Received
  PO-242 Covid 19 and practice in the Haemostasis Lab findings from a UK NEQAS (blood Coagulation) questionnaire. Ian Jennings Received Received
  PO-243 Reduction in Hospital Associated Thrombosis at Hampshire Hospitals (HHFT) due to innovative cross specialty collaboration during COVID-19 pandemic. Tracy May Received Received
  PO-244 Changes to coagulation factors in critically ill patients with SARS-CoV-2 infection Styliani Salta Received Received
  PO-245 Thrombotic complications among hospitalized Covid-19 patients in a tertiary care hospital in Karachi, Pakistan Taymmia Ejaz Received Received
  PO-246 An Audit of Warfarin to Direct Oral Anticoagulant (DOAC) Switches: Implications for the COVID-19 Era and Beyond Jayasekara Prasangika Received Received
  PO-247 Predictors for prognosis in patients with nonfatal Pulmonary Embolism in COVID19 pandemic Nadejda Diaconu Received Received
  PO-248 A multi-professional approach to improving awareness of cancer-associated thrombosis amongst people with cancer at the Northern Centre for Cancer Care in the United Kingdom Iona Cutforth Received Received
  PO-249 Prevalence of cardiovascular disease and risk factors among adult patients with haemophilia, an experience in a tertiary care hospital clinic in Sri Lanka. Thamudika Vithanage Received Received
  PO-250 Evaluation of plasma fibrinogen level in patients who have undergone extracorporeal circulation Mahjoub Sonia Received Received
  PO-251 A Rare Presentation of ST-segment Elevation Myocardial Infarction Associated with Ovarian Stimulation in the Absence of Ovarian Hyperstimulation Syndrome Keun Young Kim Received Received
  PO-252 Management appropriateness and outcomes of patients with acute pulmonary embolism in COVID-19 pandemic Nadejda Diaconu Received Received
  PO-253 Venous thromboembolism awareness among medical students in south -eastern Nigeria. A multicenter survey Helen Okoye Received Received
  PO-254 Review of Utility of Royal College of Obstetricians and Gynaecologists (RCOG) guidelines in predicting pregnancy-related VTE (PA-VTE) Bethan Myers Received Received
  PO-255 Hyperfibrinogenemia in patients with aggressive non-Hodgkins lymphoma Buruiana Sanda Received Received
  PO-256 Acquired Thrombotic Thrombocytopenic Purpura - Single Centre Experience Fatima AlKindi Received Received
  PO-257 Diagnostic uncertainty in a case of thrombotic microangiopathy Clare Brown Received Received
  PO-258 Heparin-induced thrombocytopenia: a cautionary tale Clare Brown Received Received
  PO-259 Lower Limb Oedema in Beckwith-Wiedemann Syndrome Mihai-Ionut Firescu Received Received
  PO-260 Assessment of Vitamin K Level in Newborns Presenting with Bleeding in Population of Rural Sindh, Pakistan Nazia Memon Received Received
  PO-261 A rare case of Acquired Factor 8 inhibitor in a patient with Autoimmune Hemolytic Anemia successfully treated with steroids and rituximab Pramuditha Rajapakse Received Received
  PO-262 A Rare Case of Bi-atrial Thrombi in a Stage IV Pancreatic Cancer Patient with Atrial Fibrillation on Warfarin Na Hyun Kim Received Received
  PO-263 A rare cause of diffuse peripheral and central thromboses Saad Ahmed Received Received
  PO-264 Research of influence of virus inactivating agent on the activity of Thombin Nataliia Shurko Received Received
  PO-265 Prothrombin Time, Activated Partial Thromboplastin Time and Platelets Indices of Mortuary Workers Exposed to Formaldehyde, a Base Line Study in Calabar, Nigeria Ifeyinwa Okafor Received Received
  PO-266 LONG TERM OUTCOME OF BETA THALASSEMIA MAJOR PATIENTS POST ALLOGENEIC HEMATOPOEITIC STEM CELL TRANSPLANT-A SINGLE CENTER STUDY FROM PAKISTAN Nabila Rafique Received Received
  PO-267 Outcomes of allogeneic transplantation with non-myeloablative conditioning in patients with myelodysplastic and overlap syndromes Ammar Hilali Received Received
  PO-268 Bortezomib for refractory haemolytic anaemia post allogenic haematopoietic stem cell transplantation Sophie Ganjavian Received Received
  PO-269 Incidence of veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic cell transplantation and the associated burden of disease in England: a retrospective analysis of Hospital Episode Statistics data (2010-2020) Diane Lockard Received Received
  PO-270 Outcomes of patients with acute Graft versus Host Disease managed with extra-corporeal photopheresis: a single centre service evaluation following initial commissioning by NHS England Julia Wolf Received Received
  PO-271 Variations in psychological care in UK stem cell transplant centres: results of a national survey Rosalina Naidoo Received Received
  PO-272 Cessation of ciprofloxacin prophylaxis in haemato-oncology patients at a London teaching hospital Louise Caldwell Received Received
  PO-273 Ruxolitinib for management of Graft versus host disease: Real world experience from a developing country Muhammad Yousaf Received Received
  PO-275 Influence of ABO and D antigen discrepancies in allogeneic stem cell transplant : A single center study from Bangladesh Tamanna Afroz Received Received
  PO-999 Prueba Daniel Zaldumbide Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
23:02
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

BSH 2021 VIRTUAL

 

25-28 April 2021 Virtual Conference
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 08/04/2021 TO 25/04/2022
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
 
Logo Cert